Advertisement
Document › Details
Apeiron Biologics AG. (6/3/20). "Press Release: Apeiron Biologics Closes Oversubscribed Financing Round of EUR 17.5 Million for the Development of APN01 against COVID-19". Vienna.
Expansion of the ongoing phase II clinical trial to USA and Russia planned
APEIRON Biologics AG has successfully completed a financing round totaling EUR 17.5 million, thus securing the further development of its drug candidate APN01 for the treatment of seriously ill COVID-19 patients and the further development of immuno-oncology projects. As part of a rights issue with a private placement, the company was able to raise EUR 11.9 million from existing and new private and institutional investors, including the Vienna Insurance Group (VIG), which with an investment of approx. EUR 7 million receives a participation of 3.26% in APEIRON Biologics. In addition, the Austrian Research Agency (FFG), the Vienna Business Agency (WAW), the Austria Economic Service Company (AWS) and Erste Bank have promised public funding and guarantees totaling EUR 5.6 million.
"We would like to thank our existing and new investors as well as the public institutions and banks who support our development activities for urgently needed treatment options," said Peter Llewellyn-Davies, CEO of APEIRON Biologics AG. "It is particularly gratifying that the financing round was oversubscribed and that we were also able to attract renowned and future-oriented investors as new shareholders."
About APN01
APN01 (rhACE2) is one of the most advanced drug candidates for the treatment of COVID-19 and one of the few therapy approaches specifically directed against the corona virus. According to experts, if the current phase II study is positive, accelerated market approval could probably take place.
The company plans to expand the Phase II trial, which has been launched in Austria, Germany, Denmark and the UK, to the USA and Russia. The double-blind, randomized, placebo-controlled study aims to treat 200 patients with severe COVID-19 disease.
About APEIRON Biologics AG
APEIRON Biologics AG, is a European private biotechnology company based in Vienna that specializes in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases. The approved product Qarziba(R) and APEIRON's projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.
For further information, please contact:
APEIRON Biologics AG
Peter Llewellyn-Davies, CEO
Email: investors@apeiron-biologics.com
www.apeiron-biologics.com
Media and Investor Relations
MC Services AG
Julia Hofmann
T +49 89 210 228 0
Email: apeiron@mc-services.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements that involve risks and uncertainties. These statements reflect APEIRON's opinion at the time of this press release. Such forward-looking statements are neither promises nor guarantees, but depend on many risks and uncertainties, many of which are beyond the control of APEIRON's management. This could cause actual results to differ materially from those projected in these forward-looking statements. We expressly assume no obligation to publicly update or revise any forward-looking statements regarding changed expectations of the parties or regarding new events, conditions or circumstances on which these statements are based.
Record changed: 2023-06-05 |
Advertisement
More documents for Apeiron (Group)
- [1] Apeiron Biologics AG. (4/26/22). "Press Release: Apeiron Shareholders Approve New Group Structure Geared towards Enabling Innovation and Growth". Vienna....
- [2] Apeiron Biologics AG. (11/9/20). "Press Release: Apeiron Biologics AG and Domainex Ltd Announce the Expansion of Their Partnership to Progress Targeted Cancer Immune Therapy Drug Discovery". Vienna & Saffron Waldon....
- [3] Apeiron Biologics AG. (5/18/20). "Press Release: Apeiron Biologics Announces Financing Round for the Further Development of the COVID-19 Drug APN01". Vienna....
- [4] Apeiron Biologics AG. (4/2/20). "Press Release: Apeiron Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19". Vienna....
- [5] Apeiron Biologics AG. (9/19/18). "Press Release: Apeiron Announces Collaboration with Lead Discovery Center GmbH". Vienna....
- [6] Apeiron Biologics AG. (8/28/18). "Press Release: Apeiron Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)". Vienna....
- [7] Apeiron Biologics AG. (7/17/18). "Press Release: Apeiron Appoints Peter Llewellyn-Davies as Chief Executive Officer". Vienna....
- [8] Evotec AG. (1/8/18). "Press Release: Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi". Hamburg & Vienna....
- [9] Apeiron Biologics AG. (10/13/17). "Press Release: Apeiron Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer". Vienna....
- [10] European Invesmtent Bank (EIB). (8/28/17). "Press Release: Investment Plan for Europe – EIB Grants Financing to Apeiron"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top